Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 2/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 6/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 6/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10206145 | 0.91 | NTRK1 (0.49) | TNK2NTRK1PTK2STK17A | |
| SCHEMBL10207050 | 0.91 | TNK2 (0.54) | TNK2PTK2CDK1PTK2BSTK17A | |
| SCHEMBL10205522 | 0.89 | NTRK1 (0.41) | TNK2NTRK1PTK2CDK1PTK2B | |
| SCHEMBL10207023 | 0.89 | NTRK1 (0.40) | TNK2NTRK1CDK1IGF1R | |
| SCHEMBL10207025 | 0.88 | EGFR (0.49) | TNK2NTRK1PTK2IGF1R | |
| SCHEMBL10207078 | 0.85 | STAT6 (0.40) | TNK2NTRK1PTK2CDK1PTK2B | |
| SCHEMBL10205865 | 0.84 | TNK2 (0.43) | TNK2NTRK1PTK2CDK1IGF1R | |
| SCHEMBL10205927 | 0.83 | TNK2 (0.39) | TNK2NTRK1PTK2CDK1PTK2B | |
| SCHEMBL10206634 | 0.83 | STAT6 (0.44) | TNK2PTK2CDK1PTK2BIGF1R | |
| SCHEMBL10205526 | 0.83 | WEE1 (0.46) | TNK2NTRK1PTK2CDK1PTK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655358-B1 | OXINDOLOPYRIMIDINE AS IGF1R RECEPTOR INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2014-11-19 | — | — | EP | disclosed |
| US-8546443-B2 | Benzylic oxindole pyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-20120329771-A1 | BENZYLIC OXINDOLE PYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| WO-2012085126-A1 | OXINDOLOPYRIMIDINE AS IGF1R RECEPTOR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329771-A1 | BENZYLIC OXINDOLE PYRIMIDINES | MKI67, CCNI, CCNB1 | TNK2 646/4885NTRK1 2690/4885PTK2 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.